<html xmlns:feed="http://www.w3.org/2005/Atom" xmlns:fr="http://www.feedreader.com/ns/3.0" xmlns:frc="http://www.feedreader.com/ns/3.0/frc">
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>Corporate Governance</title>
<link rel="stylesheet" href="atom.css">
<style>

body {
 font-family: verdana, tahoma;
 font-size: 0.7em;
 line-height: 1.3em;
 padding: 0;
 margin: 0;
}


a, a:link, a:active, a:visited {
 text-decoration: none;
 color: #0088ff;
}

div.entry {
 padding: 0 20px 20px 25px;
 border-bottom: 1px solid #ddd;
}

div.content img {
}

div.active {
 background-color: #f1f5fa;;
}

.read .title a {
 color: #aaa;
}


.read .content {
 color: #555;
}

div.entry .read .title a {
 color: gray;
}

.header {
 padding-top: 20px;
 margin: 0 0 0.2em 0;
}

.title {
 font-size: 1.6em;
 font-family: arial, verdana, tahoma;
 font-weight: bold;
 letter-spacing: -1px;
 line-height: 1.1em;
}

div.details {
 color: gray;
 margin-bottom: 0.5em;
}
div.clear {
 clear:both;
 height: 1px;
 width: 1px;
 font-size: 1px;
 line-height: 1px;
}
span.modified, span.author, span.category {
}

.status a {
 display:block;
 line-height: 0;
 font-size: 0;
 width: 8px; 
 height: 8px;
 margin-top: -1.5em;
 background-repeat: no-repeat;
}

.read .status a {
}






</style>
<base href="http://www.economist.com/topics/corporate-governance/">
</head>
<body>
<div class="entry" id="article5695">
<div class="header"><span class="title"><a href="http://www.economist.com/node/15213809?fsrc=rss">Novartis's bid for Alcon: In the eye</a></span><span class="status" style="float:right;"></span></div>
<div class="details"><span class="updated">05:42 1/7/2010, </span><span class="source"><a href="http://www.economist.com/topics/corporate-governance">Corporate Governance</a></span></div>
<div class="content">Issue: 
    
            
                    Bubble warning        
        


      Fly Title: 
    
            
                    Novartis's bid for Alcon
        
        


      Rubric: 
    
            
                    Minority shareholders in Swiss firms have fewer rights than they thought
        
        


      Location: 
    
            
                    Berlin
        
        

SWITZERLAND is one of the world’s oldest democracies. Yet in the corporate realm at least, as minority shareholders in Alcon—an American-listed but Swiss-based eyecare company—are discovering, some owners are more equal than others. 
On January 4th Novartis, a drug company, agreed to buy a controlling 52% stake in Alcon for $180 a share in cash to add to its existing 25% stake. Nestlé, a food giant from which Novartis is buying the stake, is already spending some of the $28.1 billion in spoils. It agreed to buy Kraft’s American pizza business for $3.7 billion. This in turn gives Kraft cash for its hostile takeover bid for Cadbury, a British confectioner. 
Alcon’s remaining shareholders are less than pleased, however. Under most countries’ takeover rules, all holders of the same class of stock must be offered the same amount of money for their shares. Yet in this case Novartis has offered to pay Alcon’s minority shareholders only $153 a share ...</div>
<div class="clear"></div>
</div>
</body>
</html>
